Jeil Pharmaceutical "Onconic Therapeutics Reveals Dual-Targeted Anticancer Drug Clinical Results at US ASCO"

[Asia Economy Reporter Hyunseok Yoo] Onconic Therapeutics (hereinafter Onconic), a subsidiary of Jeil Pharmaceutical specializing in new drug development, announced on the 25th that it will present the Phase 1 clinical trial results of the PARP and Tankyrase dual-inhibitor targeted anticancer drug 'JPI-547' at the American Society of Clinical Oncology (ASCO), which will be held online from June 4 to 8 next month.

Prior to the conference, the abstract of the 'JPI-547' paper was released on the 20th. According to the abstract, the Phase 1 efficacy evaluation was conducted on a total of 39 patients with advanced solid tumors.

Among them, partial response (PR, tumor reduction of 30% or more) was confirmed in 11 patients with ovarian cancer, breast cancer, non-small cell lung cancer, and others. The Disease Control Rate (DCR), indicating the number of patients whose tumors were controlled by drug treatment, was 64.1%, and the Overall Response Rate (ORR), indicating the number of patients with partial response, was 28.2%.

The data also included one patient out of five who showed no response to existing Olaparib treatment, whose tumor size decreased by 37%.

Jung-Hoon Kim, CEO of Onconic, said, "The ORR and DCR figures observed in the Phase 1 clinical trial on patients with advanced cancer, including the effect on patients who did not respond to existing PARP inhibitors, are very positive," adding, "We have confirmed the potential of 'JPI-547' as a PARP/Tankyrase dual-inhibitor anticancer drug, and no unusual safety issues were found. We plan to enhance the value of 'JPI-547' as a second-generation PARP anticancer drug through subsequent clinical trials."

Onconic plans to disclose more detailed data through a poster presentation at ASCO next month. The company expects 'JPI-547' to attract significant attention as a next-generation PARP anticancer drug.

ASCO (American Society of Clinical Oncology) is the world's largest cancer society, founded in 1964. Its headquarters are located in Alexandria, Virginia, USA. ASCO is one of the most prestigious cancer-related conferences worldwide, held annually in May or June. Thousands of oncology experts, as well as global pharmaceutical companies and biotech and pharmaceutical-related firms from around the world, participate in this major annual meeting.